TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $575
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice TargetHot
TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $550 to $575.
TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $550 to $575.